FGFR2 and intrahepatic cholangiocarcinoma: As in patients, FGFR inhibition in many xenograft models of FGFR2-fusion+ ICC results in modest shrinkage or stable disease rather than deep regressions, providing opportunities to investigate combination therapies23.